BioSpace News Archive

XOMA Corporation announced its Chief Executive Officer, Jim Neal, will present at the following upcoming investor conferences:

Sharecare (Nasdaq: SHCR), the digital health company that helps people manage all their health in one place, today announced that its chairman and CEO, Jeff Arnold , will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 12, 2022 at 2:15 p.m. EST .

PrecisionOS ® has added five prominent orthopedic surgeons specializing in sports-related injuries to its Clinical Advisory Board.

GeneCentric Therapeutics announced today the completion of its Piedmont Study, conducted in collaboration with Atrium Health Levine Cancer Institute.

EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene therapies and delivery solutions for liquid and solid tumors, today announced the completion of a $41 million Series B2 financing.

Menarini Group Obtains Exclusive Rights to Commercialize NEXPOVIO for the Treatment of Hematologic and Solid Tumor Oncology Indications in Europe (including the United Kingdom), Latin America and Other Key Countries.

Foldax®, Inc. today announced publication of the first clinical results for its TRIA™ biopolymer heart valve - the first polymer valve to be implanted in humans.

Pliant Therapeutics, Inc. announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant, will present a company update as part of the 40th Annual J.P Morgan Healthcare Conference.

Galectin Therapeutics Inc., the leading developer of therapeutics that target galectin proteins, announced that it has closed on the second $10 million convertible note pursuant to a financing agreement entered in September, 2021, with Richard E. Uihlein, the Company’s Chairman and largest individual stockholder.

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the full readout of safety and pharmacokinetic (PK) data from its Phase 1b study (NCT #04576325) of Inhaled Voriconazole Powder (TFF VORI) in asthma patients.